Collaborations
Proteomics-based drug discovery company signs use agreement with GlaxoSmithKline
Published in Cancer Weekly, February 8th, 2005
Under the terms of the agreement, Serenex will utilize its Proteome Mining technology to elucidate the mechanism-of-action targets and generate broad selectivity information for compounds that GSK is developing.
The agreement allows GSK scientists worldwide from any therapeutic area and stage of discovery to submit compounds to Serenex for profiling against specific tissues and cell lines. The use of Serenex's technology is aimed at enabling GSK to determine the best compounds to take forward into later stage pre-clinical and clinical development.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-02-08)
More Articles from Cancer Weekly
- Breast Cancer
Deficient DNA repair capacity associated with increased cancer risk - Breast Cancer
MIB-1 and c-erbB-2 expression influence tumor cell morphology - Cancer Surgery
Inflammatory cytokines promote tumor recurrence in lung - Environmental Health
Study: Most childhood cancers probably due to prenatal exposure to pollutants - Nasopharyngeal Carcinoma
Epstein-Barr virus DNA assessment suitable for tumor monitoring - Actinic Keratosis
Company reports positive results from phase I clinical trial for PEP005 Topical - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
